Eli Lilly and Company announced its partner Junshi Biosciences has dosed the first healthy volunteer in a study of a potential neutralizing antibody treatment designed to fight COVID-19.
Studies will evaluate the safety, tolerability, pharmacokinetics and immunogenicity of JS016 in healthy participants who have not been diagnosed with COVID-19.
Eli Lilly and Company announced its partner Junshi Biosciences has dosed the first healthy volunteer in a study of a potential neutralizing antibody treatment designed to fight COVID-19.
The experimental drug, JS016, is also expected to begin human study in the US in the second quarter of this year, through collaboration with Eli Lilly and Co.